These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 26362577

  • 1. Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.
    Maurizi N, Olivotto I, Olde Nordkamp LR, Baldini K, Fumagalli C, Brouwer TF, Knops RE, Cecchi F.
    Heart Rhythm; 2016 Feb; 13(2):457-63. PubMed ID: 26362577
    [Abstract] [Full Text] [Related]

  • 2. Prevalence of subcutaneous implantable cardioverter-defibrillator based on template ECG screening and ineligible surface ECG predicting factors in patients with hypertrophic cardiomyopathy in China.
    Guo L, Zhang M, Hu M, Wang B, Wang J, Zuo L, Yang W, Liu B, Liu L.
    Heart Vessels; 2019 May; 34(5):851-859. PubMed ID: 30465278
    [Abstract] [Full Text] [Related]

  • 3. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873684
    [Abstract] [Full Text] [Related]

  • 4. Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.
    Srinivasan NT, Patel KH, Qamar K, Taylor A, Bacà M, Providência R, Tome-Esteban M, Elliott PM, Lambiase PD.
    Circ Arrhythm Electrophysiol; 2017 Apr 12; 10(4):. PubMed ID: 28408651
    [Abstract] [Full Text] [Related]

  • 5. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B, Dale Z, Carrassa G, Reza N, Ustunkaya T, Papoutsidakis N, Gray A, Howell SJ, Elman MR, Pieragnoli P, Ricciardi G, Jacoby D, Frankel DS, Owens A, Olivotto I, Heitner SB.
    Heart Rhythm; 2020 Jul 12; 17(7):1107-1114. PubMed ID: 32084597
    [Abstract] [Full Text] [Related]

  • 6. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2015 Aug 12; 26(8):893-899. PubMed ID: 25996259
    [Abstract] [Full Text] [Related]

  • 7. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA, Sharma S, Pelchovitz DJ, Bhave PD, Rhyner J, Verma N, Arora R, Chicos AB, Kim SS, Lin AC, Passman RS, Knight BP.
    Heart Rhythm; 2014 Aug 12; 11(8):1361-6. PubMed ID: 24755323
    [Abstract] [Full Text] [Related]

  • 8. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
    Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, de Groot JR, Rosenmöller BRAM, Wilde AAM, Knops RE.
    J Cardiovasc Electrophysiol; 2014 May 12; 25(5):494-499. PubMed ID: 24320684
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
    Lambiase PD, Gold MR, Hood M, Boersma L, Theuns DAMJ, Burke MC, Weiss R, Russo AM, Kääb S, Knight BP.
    Heart Rhythm; 2016 May 12; 13(5):1066-1074. PubMed ID: 26767422
    [Abstract] [Full Text] [Related]

  • 10. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation?
    Randles DA, Hawkins NM, Shaw M, Patwala AY, Pettit SJ, Wright DJ.
    Europace; 2014 Jul 12; 16(7):1015-21. PubMed ID: 24351884
    [Abstract] [Full Text] [Related]

  • 11. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Gepner K, Pytkowski M, Kowalik I, Maczyńska-Mazuruk R, Ruzyłło W, Szwed H.
    J Cardiovasc Electrophysiol; 2010 Aug 01; 21(8):883-9. PubMed ID: 20132378
    [Abstract] [Full Text] [Related]

  • 12. Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: A prospective multicenter study.
    Campbell M, Moore JP, Sreeram N, von Alvensleben JC, Shah A, Batra A, Law I, Sanatani S, Thomas V, Nik-Ahd F, Williams S, Nosavan N, Maldonado J, Hart A, Nguyen T, Balaji S.
    Heart Rhythm; 2018 May 01; 15(5):703-707. PubMed ID: 29309839
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity and specificity of the subcutaneous implantable cardioverter defibrillator pre-implant screening tool.
    Zeb M, Curzen N, Allavatam V, Wilson D, Yue A, Roberts P, Morgan J.
    Int J Cardiol; 2015 Sep 15; 195():205-9. PubMed ID: 26048376
    [Abstract] [Full Text] [Related]

  • 14. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, Elliott PM.
    Heart; 2013 Apr 15; 99(8):534-41. PubMed ID: 23339826
    [Abstract] [Full Text] [Related]

  • 15. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 15; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 16. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, Almquist AK, Daubert JP, Lawrenz T, Boriani G, Estes NA, Favale S, Piccininno M, Winters SL, Santini M, Betocchi S, Arribas F, Sherrid MV, Buja G, Semsarian C, Bruzzi P.
    JAMA; 2007 Jul 25; 298(4):405-12. PubMed ID: 17652294
    [Abstract] [Full Text] [Related]

  • 17. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA.
    Heart; 2009 May 25; 95(9):709-14. PubMed ID: 19282314
    [Abstract] [Full Text] [Related]

  • 18. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 25; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

  • 19. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P, Gadler F, Liv P, Mörner S.
    J Cardiovasc Electrophysiol; 2015 Oct 25; 26(10):1088-94. PubMed ID: 26178879
    [Abstract] [Full Text] [Related]

  • 20. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
    Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.
    Circ Arrhythm Electrophysiol; 2018 Apr 25; 11(4):e005820. PubMed ID: 29625970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.